STOCK TITAN
  1. Home
  2. News
  3. PVCT

Provectus Biopharmaceuticals Inc - PVCT STOCK NEWS

Welcome to our dedicated news page for Provectus Biopharmaceuticals (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Provectus Biopharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Provectus Biopharmaceuticals's position in the market.

News
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
Rhea-AI Summary
Provectus Biopharmaceuticals announced the publication of preclinical data on the oral administration of Provectus Rose Bengal for solid tumor cancers. The research focused on breast, colorectal, head and neck, and testicular cancers, highlighting novel downregulation of WNK1 and Wnt signaling. The University of Calgary conducted the preclinical research, demonstrating the efficacy of Provectus's rose bengal in adult solid tumors. The findings suggest potential broader applications for treating solid tumor cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
clinical trial
-
News
Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation
Rhea-AI Summary
Provectus Biopharmaceuticals appoints Ed Pershing as CEO and Dominic Rodrigues as President, emphasizing commitment to shareholder value. Pershing brings extensive healthcare consulting experience, while Rodrigues has a background in management consulting and corporate development. The company aims to develop innovative immunotherapy medicines and enhance investor communications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.08%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. announced significant anti-tumor activity of PV-10 in head and neck cancers based on preclinical research by Moffitt Cancer Center. The research demonstrated PV-10's effectiveness in inducing immunogenic cell death and tumor regression in HPV-positive and HPV-negative head and neck squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
none
News
Provectus Biopharmaceuticals Announces Exclusive Worldwide License Agreement with University of Miami for Photodynamic Antimicrobial Treatment of Different Eye Infections with Rose Bengal Sodium
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. announced an agreement with the University of Miami for the exclusive license of PDAT technology to treat eye infections. The partnership aims to create a start-up combining the University's medical device with Provectus's rose bengal sodium for innovative treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Notices of Allowance and Award for U.S. Patents of Rose Bengal Sodium in Virology, Pediatric Solid Tumor Cancers, and Vaccines
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. announces the USPTO's allowance of three patent applications related to the use of rose bengal sodium in oncology, virology, and as a vaccine adjuvant. The patents cover various applications of the drug substance in treating infectious diseases, pediatric solid tumors, and enhancing vaccine effectiveness.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
none
-
News
Provectus Biopharmaceuticals Announces Acceptance of Cancer Immunotherapy PV-10 Abstract for HNSCC at AACR 2024 Annual Meeting
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. announces preclinical findings on PV-10 for HPV-positive and HPV-negative HNSCC, showing induction of immunogenic cell death and anti-tumor immunity. The research conducted by Moffitt Cancer Center reveals significant cytotoxicity, increase in reactive oxygen species, and markers of immunogenic cell death both in vitro and in vivo.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.41%
Tags
none
News
Provectus Biopharmaceuticals Announces Acceptance of Pharmaceutical-Grade Rose Bengal Sodium Abstract for Poster Presentation at 2024 Society for Investigative Dermatology (SID) Annual Meeting
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. announced preclinical research on the topical administration of rose bengal sodium for wound healing. The data will be presented at the annual meeting of the Society for Investigative Dermatology in May 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
-
News
Provectus Biopharmaceuticals Announces First Quarter 2024 Conference Call
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. to Host Conference Call for Company Updates on February 22, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Provectus Biopharmaceuticals Engages irlabs for Investor Relations Services
Rhea-AI Summary
Provectus Biopharmaceuticals, Inc. has partnered with IR Labs, Inc. to enhance its investor relations and corporate communications program. The collaboration aims to boost investor communication, engagement, and visibility within the investment community.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.26%
Tags
none
News
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
Rhea-AI Summary
Provectus (PVCT) has received patent approval from the USPTO for the use of its rose bengal sodium (RBS) drug substance as an adjuvant in vaccines. The patent covers the potential use in anticancer, antiviral, and other vaccines, with the potential to enhance T-cell response. The research underlying the patent was led by Dr. Aru Narendran and his lab team, with promising preclinical data presented at the SITC 2023 annual meeting. The patent award marks Provectus's first in the field of vaccines from the USPTO, with Innovate Calgary as a co-assignee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.6%
Tags
none
Stock PVCT logo
Provectus Biopharmaceuticals Inc

OTC:PVCT

PVCT Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PVCT Stock Data

70.23M
385.53M
9.42%
0.06%
0.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Knoxville

About PVCT

provectus biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. provectus’ investigational oncology drug, pv-10, is an ablative immunotherapy under investigation in solid tumor cancers.